Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 49 results.
User Information
Export Records
  1. 1.   Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective
  2. Basudhar,Debashree; Bharadwaj, Gaurav; Somasundaram,Veena; Cheng,Robert; Ridnour,Lisa; Fujita, Mayumi; Lockett,Stephen; Anderson,Steve; McVicar,Daniel; Wink,David
  3. British Journal of Pharmacology. 2019, Jan; 176(2): 155-176.
  1. 2.   The B-Raf Status of Tumor Cells May Be a Significant Determinant of Both Antitumor and Anti-Angiogenic Effects of Pazopanib in Xenograft Tumor Models
  2. Gril, B.; Palmieri, D.; Qian, Y.; Anwar, T.; Ileva, L.; Bernardo, M.; Choyke, P.; Liewehr, D. J.; Steinberg, S. M.; Steeg, P. S.
  3. Plos One. 2011, Oct; 6(10): 11.
  1. 3.   The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling
  2. Ping, Y. F.; Yao, X. H.; Jiang, J. Y.; Zhao, L. T.; Yu, S. C.; Jiang, T.; Lin, M. C. M.; Chen, J. H.; Wang, B.; Zhang, R.; Cui, Y. H.; Qian, C.; Wang, J. M.; Bian, X. W.
  3. Journal of Pathology. 2011, Jul; 224(3): 344-354.
  1. 4.   Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells
  2. Stefater, J. A.; Lewkowich, I.; Rao, S.; Mariggi, G.; Carpenter, A. C.; Burr, A. R.; Fan, J. Q.; Ajima, R.; Molkentin, J. D.; Williams, B. O.; Wills-Karp, M.; Pollard, J. W.; Yamaguchi, T.; Ferrara, N.; Gerhardt, H.; Lang, R. A.
  3. Nature. 2011, Jun; 474(7352): 511-U141.
  1. 5.   Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma
  2. Uldrick, T. S.; Whitby, D.
  3. Cancer Letters. 2011, Jun; 305(2): 150-162.
  1. 6.   A versatile valve-enabled microfluidic cell co-culture platform and demonstration of its applications to neurobiology and cancer biology
  2. Gao, Y. D.; Majumdar, D.; Jovanovic, B.; Shaifer, C.; Lin, P. C.; Zijlstra, A.; Webb, D. J.; Li, D. Y.
  3. Biomedical Microdevices. 2011, Jun; 13(3): 539-548.
  1. 7.   Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
  2. Kummar, S.; Gutierrez, M. E.; Chen, A.; Turkbey, I. B.; Allen, D.; Horneffer, Y. R.; Juwara, L.; Cao, L.; Yu, Y. K.; Kim, Y. S.; Trepel, J.; Chen, H.; Choyke, P.; Melillo, G.; Murgo, A. J.; Collins, J.; Doroshow, J. H.
  3. European Journal of Cancer. 2011, May; 47(7): 997-1005.
  1. 8.   High-Mobility Group Box-1 Mediates Toll-Like Receptor 4-Dependent Angiogenesis
  2. Lin, Q.; Yang, X. P.; Fang, D.; Ren, X. R.; Zhou, H. Y.; Fang, J. Z.; Liu, X. L.; Zhou, S. Y.; Wen, F.; Yao, X. H.; Wang, J. M.; Su, S. B.
  3. Arteriosclerosis Thrombosis and Vascular Biology. 2011, May; 31(5): 1024-U174.
  1. 9.   GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier
  2. Cullen, M.; Elzarrad, M. K.; Seaman, S.; Zudaire, E.; Stevens, J.; Yang, M. Y.; Li, X. J.; Chaudhary, A.; Xu, L. H.; Hilton, M. B.; Logsdon, D.; Hsiao, E.; Stein, E. V.; Cuttitta, F.; Haines, D. C.; Nagashima, K.; Tessarollo, L.; St Croix, B.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2011, Apr; 108(14): 5759-5764.
  1. 10.   Binding of a C-End Rule Peptide to the Neuropilin-1 Receptor: A Molecular Modeling Approach
  2. Haspel, N.; Zanuy, D.; Nussinov, R.; Teesalu, T.; Ruoslahti, E.; Aleman, C.
  3. Biochemistry. 2011, Mar; 50(10): 1755-1762.
  1. 11.   Age-related properties of the tumour vasculature in renal cell carcinoma
  2. Meehan, B.; Appu, S.; St Croix, B.; Rak-Poznanska, K.; Klotz, L.; Rak, J.
  3. Bju International. 2011, Feb; 107(3): 416-424.
  1. 12.   Hypoxia Potentiates Glioma-Mediated Immunosuppression
  2. Wei, J.; Wu, A.; Kong, L. Y.; Wang, Y. T.; Fuller, G.; Fokt, I.; Melillo, G.; Priebe, W.; Heimberger, A. B.
  3. Plos One. 2011, Jan; 6(1): 12.
  1. 13.   Current concepts regarding the HTLV-1 receptor complex
  2. Ghez, D.; Lepelletier, Y.; Jones, K. S.; Pique, C.; Hermine, O.
  3. Retrovirology. 2010, Nov; 7: 11.
  1. 14.   Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients
  2. Glynn, S. A.; Boersma, B. J.; Dorsey, T. H.; Yi, M.; Yfantis, H. G.; Ridnour, L. A.; Martin, D. N.; Switzer, C. H.; Hudson, R. S.; Wink, D. A.; Lee, D. H.; Stephens, R. M.; Ambs, S.
  3. Journal of Clinical Investigation. 2010, Nov; 120(11): 3843-3854.
  1. 15.   Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells
  2. Mathews, L. A.; Hurt, E. M.; Zhang, X. H.; Farrar, W. L.
  3. Molecular Cancer. 2010, Oct; 9: 17.
  1. 16.   Recent Development of Cyclic Amide (Pyridone/Lactam) Moiety Containing Heterocycles as Protein Kinase Inhibitors
  2. Wei, L. Y.; Malhotra, S. V.
  3. Current Medicinal Chemistry. 2010, Jan; 17(3): 234-253.
  1. 17.   Accelerated wound healing mediated by activation of Toll-like receptor 9
  2. Sato, T.; Yamamoto, M.; Shimosato, T.; Klinman, D. M.
  3. Wound Repair and Regeneration. 2010, Nov-Dec; 18(6): 586-593.
  1. 18.   The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
  2. Diaz, R.; Nguewa, P. A.; Diaz-Gonzalez, J. A.; Hamel, E.; Gonzalez-Moreno, O.; Catena, R.; Serrano, D.; Redrado, M.; Sherris, D.; Calvo, A.
  3. British Journal of Cancer. 2009 100(6): 932-940.
  1. 19.   HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF(165)
  2. Lambert, S.; Bouttier, M.; Vassy, R.; Seigneuret, M.; Petrow-Sadowski, C.; Janvier, S.; Heveker, N.; Ruscetti, F. W.; Perret, G.; Jones, K. S.; Pique, C.
  3. Blood. 2009 113(21): 5176-5185.
  1. 20.   Regulation of hypoxia-inducible genes by ETS1 transcription factor
  2. Salnikow, K.; Aprelikova, O.; Ivanov, S.; Tackett, S.; Kaczmarek, M.; Karaczyn, A.; Yee, H.; Kasprzak, K. S.; Niederhuber, J.
  3. Carcinogenesis. 2008 29(8): 1493-1499.
  1. 21.   Expression of hypoxia-inducible factor 1 alpha, hypoxia-inducible factor 2 alpha, and von Hippel-Lindau protein in epitheLiaL ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1 alpha is an independent prognostic factor in ovarian carcinoma
  2. Osada, R.; Horiuchi, A.; Kikuchi, N.; Yoshida, J.; Hayashi, A.; Ota, M.; Katsuyama, Y.; Melilo, G.; Konishi, I.
  3. Human Pathology. 2007, Sep; 38(9): 1310-1320.
  1. 22.   The anti-cancer compound Nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells
  2. Ping, Y. F.; Yao, X. H.; Chen, J. H.; Liu, H.; Chen, D. L.; Zhou, X. D.; Wang, J. M.; Bian, X. W.
  3. Journal of Neuro-Oncology. 2007, Aug; 84(1): 21-29.
  1. 23.   Hypoxia-inducible factor 1 inhibitors
  2. Melillo, G.
  3. Oxygen Biology and Hypoxia. 2007; 435 : 385-402.
  1. 24.   Inhibiting hypoxia-inducible factor 1 for cancer therapy
  2. Melillo, G.
  3. Molecular Cancer Research. 2006, Sep; 4(9): 601-605.
  1. 25.   Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis
  2. Hong, S. B.; Furihata, M.; Baba, M.; Zbar, B.; Schmidt, L. S.
  3. Laboratory Investigation. 2006, Jul; 86(7): 664-675.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel